The National Institutes of Health (NIH) recently funded an exhaustive review by the Agency for Healthcare Research and Quality (AHRQ), performed through its Evidence-Based Practice Centers. This review highlights the presence of critical gaps in current knowledge about Alzheimer’s disease (AD) and the progression of cognitive impairment. In addition to recommending continued research into the science of AD, the review emphasized the need for education to the clinicians who treat individuals with dementia to translate the latest research and emerging therapies into meaningful, clinical approaches. The recently published fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) has modified and enhanced the way clinicians will describe dementia and emphasizes the need for earlier assessment of neurocognitive disorders.
This neuroscienceCME SnackTM explores the current and emerging science in the management of individuals with AD and challenges clinicians to keep up-to-date on differential diagnosis (e.g., MCI and AD) and offer the best, evidence-based care for their patients with AD.
This is a 30-minute webcast where participants are eligible for 0.5 of a continuing education credit.
This educational activity centers on the CMEO Make One Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change Statement for this activity is:
Clinicians will use the new diagnostic language in routine clinical practice and will implement routine screening for cognitive impairment for early identification and clinical management of patients with Alzheimer’s disease.
Physicians, pharmacists, and other healthcare professionals who manage patients with Alzheimer’s disease.